Kymera Therapeutics, Inc.

Good day, everyone. My name is Shell and I will be your conference operator today. At this time, I would like to welcome you to the Chimera Therapeutics second quarter 2026 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, and if you have joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. If you have joined by phone, please press star nine on your keypad to raise your hand. At this time, I would like to turn the call over to Justine Koenigsberg, Vice President, Investor Relations.

Justine, please go ahead. Good morning and welcome to Chimera Therapeutics quarterly update conference call. Joining me today with prepared remarks are Nello Mainolfi, our founder, president and CEO, and Bruce Jacobs, our chief financial officer. We'll also have brief comments from Jared Gollub and Terrence Rooney, our new chief medical officer, who will also join us for Q&A. Following our prepared remarks, we will open the call for questions from our covering analysts. To ensure we have time to hear from everyone, we will limit each analyst to one question. Before we begin, I would like to remind you that today's discussion will include forward-looking statements subject to risks and uncertainties described in our most recent Form 10-Q filed with the SEC. Please note that any forward-looking statements speak only as of today's date, and we undertake no obligation to update them. With that I will now turn the call over to Nello.

Thank you, Justine, and good morning, everyone. Before we dive into the quarterly update, as we announced last week, I'd like to take a moment to recognize Jared as he prepares to retire and thank him for his many contributions over the past eight years. Jared has been instrumental in helping build Chimera and has made a meaningful impact across virtually every aspect of the company. His leadership, dedication, and partnership have helped shape where we are today, and we're incredibly grateful for everything he's done. While we certainly miss him, he leaves the organization in a position of great strength. With Terence stepping into the role, I'm confident that we'll have a seamless transition and continue to build on the strong foundation Jared has helped create. You'll hear from Terence later in the call, but I'm very excited to have him join the team and believe there is long and deep experience across all phases of immunology development and commercialization, along with his insights and capabilities will be critical to helping advance our next phase of growth. On behalf of everybody at Chimera, thank you, Jared. We wish you nothing but the very best in this well-deserved next chapter. Before we get started, we wanted to give him the opportunity to share a few words. Jared.